Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Fig. 4

Case analysis of two patients with MSAF decreased but bITH up after treatment experienced disease progression as the best response to treatment. A, C The timeline, treatment history, and radiographic response to treatment of the patient P12 (A) and P03 (C). B, D The changes of bITH score, tumor size, and detected somatic mutations at baseline and after two cycles of therapy in patient P12 (B) and P03 (D). Hierarchical clustering method was used to cluster somatic mutations detected at two time points. bITH, blood-based intratumor heterogeneity; PD, progressive disease; MSAF, maximum somatic allele frequency; MAF, mutant allele frequency

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us